AlenCiken

Launches Covid-19 Antibody Test in its CLIA laboratory

NASDAQ:PRPO   Precipio, Inc.
Precipio Launches Covid-19 Antibody Test in its CLIA laboratory

Completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory.

Launched the test commercially to its pathology customer base (phase 1)

Upon obtaining further approval for expanded use by FDA, phase 2 will broaden our distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices.

Precipio is currently able to process 1,000 tests per day, increasing testing capacity to 10,000 tests per day by the end of Q3-20 as demand grows.

Reimbursement is approximately $45 per test.

finance.yahoo.c...-144500207.html?guce_refer...

Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.